SER recommendations on the use of biological drugs in primary Sjögren's syndrome

Sánchez, J. L. Andréu; Castro, M. Fernández; Fontecha, Petra Díaz del Campo; Corominas, H.; García, Francisco Javier Narváez; Rúa-Figueroa, Íñigo; Hernández, Miguel Ángel Abad; Rivas, María Noelia Álvarez; Montes, Javier del Pino; Hernández, Félix Manuel Francisco; Pedraza, María Ángeles Gantes; Greco, Martin; Hernández, María Vanesa; Compán, M. V. Navarro; Solarte, Juan Alberto Paz; Bueno, Fredeswinda Isabel Romero; Park, Hye-Sang; Mascaró, Francisca Sivera

doi:10.1016/j.reumae.2018.10.017

Cited by 2 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RTX has been approved by the EMA and FDA for the treatment of lymphoproliferative syndromes, rheumatoid arthritis, ANCA-associated vasculitis and pemphigus vulgaris. Moreover, RTX treatment may be considered in organ-threatening, refractory systemic lupus erythematosus [ 32 ] and in refractory severe extra-glandular manifestations in patients with primary Sjögren’s syndrome [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

Atienza‐Mateo

Remuzgo‐Martínez

Prieto-Peña

et al. 2020

JCM

View full text Add to dashboard Cite

In the present study, we aimed to report our experience with rituximab (RTX) in the treatment of patients with ILD associated with AD (AD-ILD) at a single center. For this purpose, clinical characteristics, radiological findings, and pulmonary function tests (PFTs) of RTX-treated AD-ILD-patients seen from May 2016 until March 2020 at a referral center for individuals with ILD were retrospectively reviewed. Additionally, an updated literature review was conducted. A total of 26 patients (mean age 58.3 ± 11.1 years at ILD diagnosis) was included. The most common ADs related to ILD were systemic sclerosis, idiopathic inflammatory myositis (including anti-synthetase syndrome) and rheumatoid arthritis. Non-specific interstitial pneumonia (n = 12) and usual interstitial pneumonia (n = 11) were the predominant radiological patterns. The sustained improvement in PFTs was observed from the start of RTX, with a statistically significant increase in DLCO from basal to one year after RTX (mean + 4.2%, p = 0.024). Overall, there were no differences when comparing PFT outcome according to the radiological pattern or the specific type of AD. In conclusion, RTX constitutes a good therapeutic option to preserve lung function in patients with AD-ILD, regardless of the radiological pattern or the underlying AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

Atienza‐Mateo

Remuzgo‐Martínez

Prieto-Peña

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Moreover, TNF-α-induced matrix metallopeptidase 9 caused damages on extracellular matrix in exocrine glands, which could be prevented by anti-TNF-α agent [45]. Anti-TNF agents are now used in pSS [46] but have not received positive results in other studies due to the diverse effects of TNF-α on immune cell subsets [47].…”

Section: Tnf-αmentioning

confidence: 99%

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

Zeng

Zhou

et al. 2022

IJMS

View full text Add to dashboard Cite

Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease defined by exocrine gland hypofunction resulting in dry eyes and dry mouth. Despite increasing interest in biological therapies for pSS, achieving FDA-approval has been challenging due to numerous complications in the trials. The current literature lacks insight into a molecular-target-based approach to the development of biological therapies. This review focuses on novel research in newly defined drug targets and the latest clinical trials for pSS treatment. A literature search was conducted on ClinicalTrials.gov using the search term “Primary Sjögren’s syndrome”. Articles published in English between 2000 and 2021 were included. Our findings revealed potential targets for pSS treatment in clinical trials and the most recent advances in understanding the molecular mechanisms underlying the pathogenesis of pSS. A prominent gap in current trials is in overlooking the treatment of extraglandular symptoms such as fatigue, depression, and anxiety, which are present in most patients with pSS. Based on dryness and these symptom-directed therapies, emerging biological agents targeting inflammatory cytokines, signal pathways, and immune reaction have been studied and their efficacy and safety have been proven. Novel therapies may complement existing non-pharmacological methods of alleviating symptoms of pSS. Better grading systems that add extraglandular symptoms to gauge disease activity and severity should be created. The future of pSS therapies may lie in gene, stem-cell, and tissue-engineering therapies.

show abstract

SER recommendations on the use of biological drugs in primary Sjögren's syndrome

Cited by 2 publications

References 68 publications

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

Contact Info

Product

Resources

About